
{
  "Company Overview": {
    "Name": "Samrat Pharmachem Ltd",
    "Sector": "Pharmaceuticals",
    "Industry": "Pharmaceuticals - Indian - Bulk Drugs",
    "Business Description": "Incorporated in 1992, Samrat Pharmachem Ltd does manufacturing and selling of chemicals. SPL manufactures pharmaceutical ingredient products. It is a major supplier of Iodine Derivatives to the Indian and Foreign Market and is also present in Salt, Animal Feed, Textile & Tyre Cord manufacturing segment. Company's facilities approved by leading regulatory agencies such as USFDA, GMP, EU GMP, UK MHRA, South Africa-MCC, Health Canada, WHO and Brazil ANVISA",
    "Market Position": "Major supplier of Iodine Derivatives to the Indian and Foreign Market"
  },
  "Financial Metrics": {
    "Market Cap": "₹ 124 Cr.",
    "Current Price": "₹ 401",
    "High/Low": "₹ 646 / ₹ 320",
    "Stock P/E": 19.2,
    "Book Value": "₹ 225",
    "Dividend Yield": "0.25 %",
    "ROCE": "4.11 %",
    "ROE": "3.34 %",
    "Face Value": "₹ 10.0"
  },
  "Performance Trends": {
    "Quarterly Results": {
      "Sales": {
        "Sep 2021": 59.08,
        "Dec 2021": 55.34,
        "Mar 2022": 60.10,
        "Jun 2022": 86.50,
        "Sep 2022": 71.12,
        "Dec 2022": 83.85,
        "Mar 2023": 69.18,
        "Jun 2023": 57.48,
        "Sep 2023": 79.74,
        "Dec 2023": 61.67,
        "Mar 2024": 82.68,
        "Jun 2024": 80.82,
        "Sep 2024": 70.17
      },
      "Expenses": {
        "Sep 2021": 54.92,
        "Dec 2021": 46.73,
        "Mar 2022": 50.03,
        "Jun 2022": 73.62,
        "Sep 2022": 62.86,
        "Dec 2022": 80.57,
        "Mar 2023": 69.67,
        "Jun 2023": 56.71,
        "Sep 2023": 79.51,
        "Dec 2023": 61.56,
        "Mar 2024": 81.32,
        "Jun 2024": 78.24,
        "Sep 2024": 66.80
      },
      "Operating Profit": {
        "Sep 2021": 4.16,
        "Dec 2021": 8.61,
        "Mar 2022": 10.07,
        "Jun 2022": 12.88,
        "Sep 2022": 8.26,
        "Dec 2022": 3.28,
        "Mar 2023": -0.49,
        "Jun 2023": 0.77,
        "Sep 2023": 0.23,
        "Dec 2023": 0.11,
        "Mar 2024": 1.36,
        "Jun 2024": 2.58,
        "Sep 2024": 3.37
      },
      "OPM %": {
        "Sep 2021": "7.04%",
        "Dec 2021": "15.56%",
        "Mar 2022": "16.76%",
        "Jun 2022": "14.89%",
        "Sep 2022": "11.61%",
        "Dec 2022": "3.91%",
        "Mar 2023": "-0.71%",
        "Jun 2023": "1.34%",
        "Sep 2023": "0.29%",
        "Dec 2023": "0.18%",
        "Mar 2024": "1.64%",
        "Jun 2024": "3.19%",
        "Sep 2024": "4.80%"
      },
      "Net Profit": {
        "Sep 2021": 2.79,
        "Dec 2021": 6.45,
        "Mar 2022": 7.00,
        "Jun 2022": 9.37,
        "Sep 2022": 5.91,
        "Dec 2022": 2.10,
        "Mar 2023": -0.74,
        "Jun 2023": 0.61,
        "Sep 2023": -0.19,
        "Dec 2023": 0.34,
        "Mar 2024": 1.40,
        "Jun 2024": 2.07,
        "Sep 2024": 2.66
      }
    },
    "Annual Results": {
      "Sales": {
        "Mar 2013": 72,
        "Mar 2014": 65,
        "Mar 2015": 47,
        "Mar 2016": 63,
        "Mar 2017": 73,
        "Mar 2018": 93,
        "Mar 2019": 111,
        "Mar 2020": 137,
        "Mar 2021": 179,
        "Mar 2022": 222,
        "Mar 2023": 311,
        "Mar 2024": 282,
        "TTM": 295
      },
      "Net Profit": {
        "Mar 2013": 0,
        "Mar 2014": 0,
        "Mar 2015": 0,
        "Mar 2016": 0,
        "Mar 2017": 2,
        "Mar 2018": 3,
        "Mar 2019": 2,
        "Mar 2020": 4,
        "Mar 2021": 5,
        "Mar 2022": 17,
        "Mar 2023": 17,
        "Mar 2024": 2,
        "TTM": 6
      }
    }
  },
  "Ratios": {
    "Growth Ratios": {
      "Compounded Sales Growth": {
        "10 Years": "16%",
        "5 Years": "20%",
        "3 Years": "16%",
        "TTM": "2%"
      },
      "Compounded Profit Growth": {
        "10 Years": "24%",
        "5 Years": "7%",
        "3 Years": "-26%",
        "TTM": "263%"
      },
      "Stock Price CAGR": {
        "10 Years": "31%",
        "5 Years": "35%",
        "3 Years": "8%",
        "1 Year": "13%"
      }
    },
    "Liquidity Ratios": {
      "Debtor Days": {
        "Mar 2013": 60,
        "Mar 2014": 63,
        "Mar 2015": 74,
        "Mar 2016": 93,
        "Mar 2017": 59,
        "Mar 2018": 86,
        "Mar 2019": 69,
        "Mar 2020": 74,
        "Mar 2021": 67,
        "Mar 2022": 72,
        "Mar 2023": 61,
        "Mar 2024": 90
      },
      "Inventory Days": {
        "Mar 2013": 54,
        "Mar 2014": 45,
        "Mar 2015": 38,
        "Mar 2016": 37,
        "Mar 2017": 41,
        "Mar 2018": 31,
        "Mar 2019": 28,
        "Mar 2020": 55,
        "Mar 2021": 25,
        "Mar 2022": 24,
        "Mar 2023": 43,
        "Mar 2024": 28
      },
      "Days Payable": {
        "Mar 2013": 89,
        "Mar 2014": 87,
        "Mar 2015": 76,
        "Mar 2016": 104,
        "Mar 2017": 43,
        "Mar 2018": 46,
        "Mar 2019": 45,
        "Mar 2020": 67,
        "Mar 2021": 39,
        "Mar 2022": 45,
        "Mar 2023": 42,
        "Mar 2024": 64
      },
      "Cash Conversion Cycle": {
        "Mar 2013": 25,
        "Mar 2014": 21,
        "Mar 2015": 36,
        "Mar 2016": 26,
        "Mar 2017": 58,
        "Mar 2018": 70,
        "Mar 2019": 52,
        "Mar 2020": 61,
        "Mar 2021": 53,
        "Mar 2022": 51,
        "Mar 2023": 62,
        "Mar 2024": 53
      },
      "Working Capital Days": {
        "Mar 2013": 37,
        "Mar 2014": 25,
        "Mar 2015": 39,
        "Mar 2016": 35,
        "Mar 2017": 61,
        "Mar 2018": 65,
        "Mar 2019": 56,
        "Mar 2020": 63,
        "Mar 2021": 54,
        "Mar 2022": 44,
        "Mar 2023": 62,
        "Mar 2024": 58
      }
    },
    "Profitability Ratios": {
      "ROCE %": {
        "Mar 2013": "9%",
        "Mar 2014": "7%",
        "Mar 2015": "7%",
        "Mar 2016": "5%",
        "Mar 2017": "16%",
        "Mar 2018": "23%",
        "Mar 2019": "12%",
        "Mar 2020": "22%",
        "Mar 2021": "24%",
        "Mar 2022": "52%",
        "Mar 2023": "35%",
        "Mar 2024": "4%"
      },
      "Return on Equity": {
        "10 Years": "19%",
        "5 Years": "22%",
        "3 Years": "23%",
        "Last Year": "3%"
      }
    },
    "Valuation Ratios": {
      "Price to Book": null 
    }
  },
  "Peer Comparison": {
    "Peers": [
      {"Name": "Divi's Lab.", "CMP": 5846.75, "P/E": 84.54, "Mar Cap": 155212.84, "Div Yld": 0.51, "NP Qtr": 510.00, "Qtr Profit Var": 46.55, "Sales Qtr": 2338.00, "Qtr Sales Var": 22.47, "ROCE": 16.48},
      {"Name": "Neuland Labs.", "CMP": 13891.15, "P/E": 67.48, "Mar Cap": 17822.19, "Div Yld": 0.10, "NP Qtr": 32.84, "Qtr Profit Var": -63.20, "Sales Qtr": 310.84, "Qtr Sales Var": -25.59, "ROCE": 33.26},
      {"Name": "Jubilant Pharmo", "CMP": 1061.60, "P/E": 59.42, "Mar Cap": 16911.29, "Div Yld": 0.47, "NP Qtr": 102.50, "Qtr Profit Var": 81.29, "Sales Qtr": 1752.30, "Qtr Sales Var": 4.28, "ROCE": 6.74},
      {"Name": "Ami Organics", "CMP": 2120.40, "P/E": 92.93, "Mar Cap": 8679.74, "Div Yld": 0.14, "NP Qtr": 37.56, "Qtr Profit Var": 387.34, "Sales Qtr": 246.73, "Qtr Sales Var": 43.15, "ROCE": 15.99},
      {"Name": "Hikal", "CMP": 378.40, "P/E": 63.53, "Mar Cap": 4665.70, "Div Yld": 0.32, "NP Qtr": 18.30, "Qtr Profit Var": 45.58, "Sales Qtr": 452.90, "Qtr Sales Var": 4.14, "ROCE": 7.79},
      {"Name": "Aarti Drugs", "CMP": 428.25, "P/E": 31.48, "Mar Cap": 3937.12, "Div Yld": 0.23, "NP Qtr": 30.39, "Qtr Profit Var": -12.12, "Sales Qtr": 543.09, "Qtr Sales Var": -5.96, "ROCE": 13.68},
      {"Name": "Guj. Themis Bio.", "CMP": 307.85, "P/E": 63.64, "Mar Cap": 3354.50, "Div Yld": 0.22, "NP Qtr": 10.57, "Qtr Profit Var": -15.71, "Sales Qtr": 34.72, "Qtr Sales Var": -12.19, "ROCE": 44.99}
    ],
    "Median": {
      "CMP": 276.15,
      "P/E": 33.95,
      "Mar Cap": 409.76,
      "Div Yld": 0.12,
      "NP Qtr": 6.98,
      "Qtr Profit Var": 36.86,
      "Sales Qtr": 76.58,
      "Qtr Sales Var": 14.86,
      "ROCE": 13.88
    }
  },
  "Other Insights": {
    "Pros": "Company has reduced debt.",
    "Cons": "Debtor days have increased from 74.1 to 89.8 days.",
    "Disclaimer": "The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.",
    "Shareholding Pattern Notes": "* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards. Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes. Click on the line-items to see the names of individual entities."
  },
  "Documents": {
    "Announcements": [
      {"Date": "21 Nov", "Title": "Announcement under Regulation 30 (LODR)-Newspaper Publication"},
      {"Date": "14 Nov", "Title": "Board Meeting Outcome for Un-Audited Financial Results For The Quarter And Half Year Ended September 30, 2024"},
      {"Date": "18 Oct", "Title": "Certificate under Regulation 74(5) for Q3 2024."},
      {"Date": "27 Sep", "Title": "Closure of Trading Window"}
    ],
    "Annual Reports": [
      {"Year": 2024, "Source": "bse"},
      {"Year": 2023, "Source": "bse"},
      {"Year": 2022, "Source": "bse"},
      {"Year": 2021, "Source": "bse"},
      {"Year": 2020, "Source": "bse"},
      {"Year": 2019, "Source": "bse"},
      {"Year": 2018, "Source": "bse"},
      {"Year": 2017, "Source": "bse"},
      {"Year": 2016, "Source": "bse"},
      {"Year": 2015, "Source": "bse"},
      {"Year": 2014, "Source": "bse"},
      {"Year": 2013, "Source": "bse"},
      {"Year": 2012, "Source": "bse"},
      {"Year": 2011, "Source": "bse"},
      {"Year": 2010, "Source": "bse"}
    ],
    "Credit Ratings": [
      {"Date": "27 Feb", "Source": "crisil"},
      {"Date": "11 Jan", "Source": "crisil"},
      {"Date": "30 Dec 2022", "Source": "crisil"},
      {"Date": "21 Dec 2022", "Source": "crisil"},
      {"Date": "26 Apr 2022", "Source": "crisil"},
      {"Date": "11 Mar 2022", "Source": "crisil"}
    ]
  }
}
